Note that there are drugs in development as sub-cutaneous (SC) administration (like current Ozempic, Wegovy, Zepbound, Mounjaro), whilst we wont need to wait to long for the oral versions of these drugs to come out (next 6-12 months)
Strictly for research use only
The challenge is that many people find themselves gaining weight after they stop taking them, sometimes called the Ozempic Rebound
Retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors simultaneously, whereas semaglutide targets only GLP-1 and tirzepatide targets GLP-1 and GIP
Eli Lillys orforglipron (a non-peptide oral GLP-1) is tracking toward FDA approval by summer 2026 at a similar $149 starting price, and Ro has it listed as Foundayo
AI just analyzed 5+ years of Reddit posts and caught what the clinical trial process missed: unreported side effects from the most popular drugs in America